Skip to main content
Premium Trial:

Request an Annual Quote

Bioke, Trinean Ink Distribution Agreement

NEW YORK (GenomeWeb News) – Bioké has signed an agreement to distribute Trinean products in the Netherlands and Germany, the firms announced today.

Trinean's Xpose 'Touch & Go" platform is for quantifying DNA, RNA, and proteins, while the DropSense96 instrument quantifies DNA, RNA, and proteins without dyes in a microvolume 96-well format.

Bioké, based in Leiden, the Netherlands, is a cell signaling technology firm. "The addition of high quality Trinean products in the Bioké portfolio strengthens our ability to provide complete solutions to customers in academic institutions, hospitals, and in the pharmaceutical and biotechnology industries," Bioké Director of Sales and Operations Koos Kranenborg said in a statement.

Ghent, Belgium-based Trinean on Thursday announced a deal to supply its instruments to Bayer CropScience for that firm's molecular breeding program.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.